Clinical Trial Update: XVIE to Treat Androgenetic Alopecia (AGA) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update indicates XVIE is planned for Phase 1/2 testing to treat androgenetic alopecia, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• XVIE

Snippet

Sponsor: Restore Biologics Holdings, Inc. dba Xtressé | Conditions: Androgenetic Alopecia | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING